|
Drug toxicity/efficacy (Over 1000 studies/reports)
INDs / NDAs /NADAs (Over 30 Toxicology/Pharmacology Sections)
Investig Brochures, Introductory Statements, Annual Reports
Carcinogenicity testing and evaluation (Over 100)
Maximum Tolerated Dose (MTD),(Publications)
Mutagenicity testing and evaluation
GLP compliance (Expert opinion)
GLP SOP Manuals (Preparation)
Acrylates, safety (IND)
Lipid lowering drugs (IND)
Anti-inflammatories (IND)
Carnitine, and derivatives (IND, NDA)
Anti-Parkinson drugs (Levodopa, Carbidopa) (IND)
Breast cancer: Classification, Therapy Guidelines(Panel)
Immunosuppression, experimental (Study)
Aldosterone antagonists: Mammary effects (Comment)
Drug impurities (Expert opinion)
|
Cisplatin: Active anaphylaxis (Study)
Somatotropin safety (Publication)
Red No3 Carcinogenicity (FDA Peer Review Panel)
Dehydroepiandrosterone (Expert Review Panel)
Psoralens (Publication)
Olestra (Safety) (Expert opinion)
Sucralose (Safety) (Expert opinion)
Pesticides (Efficacy and Safety) (Publications)
Bendazon (EPA External Peer Review Panel)
Dioxin (Toxicity), EPA report (Expert opinion)
Environmental tobacco exposure (Expert opinion)
Electromagnetic fields (Expert opinion)
Standard Biomedical Nomenclature Database (FDA grant)
Animal experimentation and husbandry: Food intake
Mortality of rats during long-term studies (Comment)
Dosage levels spacing in toxicity studies (Comment)
Blood effect of fasting (Publication)
Gavage v dietary administration (Publication)
Dose calculations (Publication)
Animal welfare (Committee Chairman)
|